|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SGOL1 |
Gene summary for SGOL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SGOL1 | Gene ID | 151648 |
| Gene name | shugoshin 1 | |
| Gene Alias | CAID | |
| Cytomap | 3p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B5BUA4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151648 | SGOL1 | P79T-E | Human | Esophagus | ESCC | 9.56e-08 | 2.44e-01 | 0.1154 |
| 151648 | SGOL1 | P83T-E | Human | Esophagus | ESCC | 1.27e-09 | 3.67e-01 | 0.1738 |
| 151648 | SGOL1 | P89T-E | Human | Esophagus | ESCC | 6.02e-08 | 5.03e-01 | 0.1752 |
| 151648 | SGOL1 | P91T-E | Human | Esophagus | ESCC | 4.77e-11 | 1.26e+00 | 0.1828 |
| 151648 | SGOL1 | P107T-E | Human | Esophagus | ESCC | 1.01e-07 | 2.11e-01 | 0.171 |
| 151648 | SGOL1 | P128T-E | Human | Esophagus | ESCC | 9.55e-03 | 1.70e-01 | 0.1241 |
| 151648 | SGOL1 | P130T-E | Human | Esophagus | ESCC | 3.28e-14 | 3.75e-01 | 0.1676 |
| 151648 | SGOL1 | C04 | Human | Oral cavity | OSCC | 3.59e-05 | 3.62e-01 | 0.2633 |
| 151648 | SGOL1 | C21 | Human | Oral cavity | OSCC | 1.56e-10 | 3.83e-01 | 0.2678 |
| 151648 | SGOL1 | C30 | Human | Oral cavity | OSCC | 1.90e-10 | 5.52e-01 | 0.3055 |
| 151648 | SGOL1 | C38 | Human | Oral cavity | OSCC | 3.61e-03 | 5.95e-01 | 0.172 |
| 151648 | SGOL1 | C43 | Human | Oral cavity | OSCC | 4.24e-06 | 1.49e-01 | 0.1704 |
| 151648 | SGOL1 | C46 | Human | Oral cavity | OSCC | 2.87e-13 | 3.13e-01 | 0.1673 |
| 151648 | SGOL1 | C51 | Human | Oral cavity | OSCC | 1.33e-05 | 2.99e-01 | 0.2674 |
| 151648 | SGOL1 | C57 | Human | Oral cavity | OSCC | 2.86e-09 | 3.35e-01 | 0.1679 |
| 151648 | SGOL1 | C08 | Human | Oral cavity | OSCC | 9.07e-06 | 2.08e-01 | 0.1919 |
| 151648 | SGOL1 | LN22 | Human | Oral cavity | OSCC | 5.72e-05 | 4.96e-01 | 0.1733 |
| 151648 | SGOL1 | LN46 | Human | Oral cavity | OSCC | 8.19e-11 | 5.11e-01 | 0.1666 |
| 151648 | SGOL1 | SYSMH2 | Human | Oral cavity | OSCC | 3.94e-04 | 1.80e-01 | 0.2326 |
| 151648 | SGOL1 | SYSMH3 | Human | Oral cavity | OSCC | 3.41e-13 | 3.09e-01 | 0.2442 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |